Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 290 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IVIg Clear all
Not listed Phase 2 Interventional

Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism

NCT00110708
View directory record Official record
Conditions
Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases, Signs and Symptoms, Digestive
Interventions
Oralgam (human immunoglobulin)
Drug
Lead sponsor
PediaMed Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2006 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

NCT02040090
View directory record Official record
Conditions
Rabies
Interventions
Active rabies vaccine (US-FDA approved)
Drug
Lead sponsor
Kamada, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 3, 2026, 11:02 AM EDT
Active, not recruiting Phase 3 Interventional

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

NCT04944979
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
2 Years to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Centennial, Colorado • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 11:02 AM EDT
Withdrawn Phase 1 Interventional

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

NCT02042027
View directory record Official record
Conditions
Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
Interventions
Gamunex-C
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

NCT00606905
View directory record Official record
Conditions
Miscarriage, Recurrent, Abortion, Habitual
Interventions
Gamimune N or Gamunex 10%, normal saline
Biological · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Sep 3, 2026, 11:02 AM EDT
Completed No phase listed Observational

Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies

NCT01451879
View directory record Official record
Conditions
Pompe Disease
Interventions
Rituximab, Miglustat
Drug
Lead sponsor
University of Florida
Other
Eligibility
Up to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

NCT02122081
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
radiation therapy, cyclophosphamide, anti-thymocyte globulin, tacrolimus, methotrexate, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
Radiation · Drug · Biological + 2 more
Lead sponsor
Sumithira Vasu
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease

NCT00841789
View directory record Official record
Conditions
Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Michael Portman
Other
Eligibility
2 Months to 20 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
7
States / cities
New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 3, 2026, 11:02 AM EDT
Recruiting Phase 3 Interventional

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
riliprubart, Placebo, IVIg
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
33
States / cities
Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 11:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cell Transplantation in Crohn's Disease

NCT04224558
View directory record Official record
Conditions
Crohn Disease
Interventions
Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
Drug · Procedure · Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years to 28 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 3, 2026, 11:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome

NCT00806182
View directory record Official record
Conditions
Opsoclonus-myoclonus Syndrome
Interventions
Not listed
Lead sponsor
National Pediatric Neuroinflammation Organization, Inc.
Other
Eligibility
1 Year to 18 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies

NCT00001261
View directory record Official record
Conditions
Dermatomyositis, Inclusion Body Myositis, Polymyositis
Interventions
Gamma Globulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

NCT00782106
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Recombinant human hyaluronidase + immune globulin intravenous
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
16 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 3, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

IVIG for Infection Prevention After CAR-T-Cell Therapy

NCT05952804
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review
Biological · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 1 Interventional

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

NCT02240407
View directory record Official record
Conditions
Pompe Disease
Interventions
Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream
Genetic · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Study of Human Botulism Immunoglobulin in Infants With Botulism

NCT00004401
View directory record Official record
Conditions
Infant Botulism, Botulism
Interventions
botulism immune globulin
Drug
Lead sponsor
California Department of Health Services
Other
Eligibility
Up to 1 Year
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

NCT02783482
View directory record Official record
Conditions
Immunologic Deficiency Syndromes
Interventions
GC5107
Biological
Lead sponsor
Green Cross Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
10
States / cities
Centennial, Colorado • North Palm Beach, Florida • Plymouth, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 3, 2026, 11:02 AM EDT
Withdrawn Phase 2 Interventional

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

NCT05701189
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg)
Drug
Lead sponsor
Chafic Karam
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

NCT01203345
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions
IVIG, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 72 Hours
Enrollment
2,416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 1991
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

NCT02728752
View directory record Official record
Conditions
Dermatomyositis
Interventions
Octagam 10%, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years to 79 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Huntington Beach, California • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

NCT02955355
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
HYQVIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

NCT01376778
View directory record Official record
Conditions
Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Interventions
CMV hyperimmune globulin, Placebo
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 3, 2026, 11:02 AM EDT
Withdrawn Phase 2 Interventional

Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B

NCT03575208
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
hepatitis B immune globulin (HBIg), Pegylated interferon alfa (pegIFN)
Biological · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 3, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration

NCT00034242
View directory record Official record
Conditions
Spinocerebellar Degenerations
Interventions
high-dose intravenous immunoglobulin (IVIG)
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 11:02 AM EDT